Amoxicillin/ceftriaxone

  • PDF / 169,766 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 83 Downloads / 146 Views

DOWNLOAD

REPORT

1 S

Allergy and treatment failure: 3 case reports In an observational study of 16 patients who had been diagnosed between 2007 and 2017 at a hospital in France, 3 patients (1 man and 2 women) aged 23–60 years were described, of whom two patients exhibited treatment failure with ceftriaxone or amoxicillin for neuroborreliosis and the remaining patient developed allergy during treatment with ceftriaxone for neuroborreliosis [not all dosages and routes stated; durations of treatments to reactions onsets and outcomes not stated]. Case 1: A 54-year-old man was diagnosed with chronic demyelinating neuropathy following meningitis due to neuroborreliosis. He then received IV ceftriaxone 2g daily for one month, but his neurological symptoms continued to worsen with onset of amyotrophy in the lower limbs, suggestive of treatment failure. He was treated with unspecified immunoglobulins and unspecified corticosteroids. She also underwent sessions of plasma exchange and azathioprine was also initiated, which led to disease stability. His functional recovery was limited due to axonal loss. Case 2: A 60-year-old woman was diagnosed with meningoradiculoneuritis due to neuroborreliosis. She the started receiving IV ceftriaxone. However, she subsequently developed allergy to ceftriaxone. Ceftriaxone was therefore switched to doxycycline. Case 3: A 23-year-old woman was diagnosed with meningoradiculoneuritis due to neuroborreliosis. She then received treatment with amoxicillin for 3 weeks. However, this treatment was found to be failed. Amoxicillin was therefore switched to ceftriaxone. Kaminsky AL, et al. Confirmed cases of Neuroborreliosis with involvement of peripheral nervous system: Description of a cohort. Medicine 99: No. 40, 2 Oct 2020. Available 803517822 from: URL: http://doi.org/10.1097/MD.0000000000021986

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832

Data Loading...